 Mechanistic Target of Rapamycin Complex 1
"Mechanistic Target of Rapamycin Complex 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An evolutionarily conserved multiprotein complex that functions as a cellular energy sensor and regulator of protein synthesis for cell growth and proliferation. It consists of TOR SERINE-THREONINE KINASES; REGULATORY-ASSOCIATED PROTEIN OF MTOR (RAPTOR); MLST8 PROTEIN; and AKT1 substrate 1 protein. The activity of the complex is regulated by SIROLIMUS; INSULIN; GROWTH FACTORS; PHOSPHATIDIC ACIDS; some amino acids or amino acid derivatives, and OXIDATIVE STRESS.
| Descriptor ID |
D000076222
|
| MeSH Number(s) |
D05.500.337 D08.811.913.696.620.682.700.931.500 D12.776.476.925.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mechanistic Target of Rapamycin Complex 1".
Below are MeSH descriptors whose meaning is more specific than "Mechanistic Target of Rapamycin Complex 1".
This graph shows the total number of publications written about "Mechanistic Target of Rapamycin Complex 1" by people in this website by year, and whether "Mechanistic Target of Rapamycin Complex 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 3 | 3 | | 2013 | 0 | 6 | 6 | | 2014 | 0 | 5 | 5 | | 2015 | 0 | 8 | 8 | | 2016 | 1 | 0 | 1 | | 2017 | 2 | 4 | 6 | | 2018 | 0 | 1 | 1 | | 2019 | 2 | 1 | 3 | | 2020 | 1 | 3 | 4 | | 2021 | 3 | 3 | 6 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 3 | 3 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mechanistic Target of Rapamycin Complex 1" by people in Profiles.
-
Dumolt JH, Rosario FJ, Barentsen K, Urschitz J, Powell TL, Jansson T. Trophoblast-specific overexpression of adiponectin receptor 2 causes fetal growth restriction in pregnant mice. FASEB J. 2024 Oct 15; 38(19):e70100.
-
Chalkley ML, Mersfelder RB, Sundberg M, Armstrong LC, Sahin M, Ihrie RA, Ess KC. Non-canonical functions of a mutant TSC2 protein in mitotic division. PLoS One. 2023; 18(10):e0292086.
-
Sri Hari A, Banerji R, Liang LP, Fulton RE, Huynh CQ, Fabisiak T, McElroy PB, Roede JR, Patel M. Increasing glutathione levels by a novel posttranslational mechanism inhibits neuronal hyperexcitability. Redox Biol. 2023 11; 67:102895.
-
Rosario FJ, Chopra A, Biggar K, Powell TL, Gupta MB, Jansson T. Placental Remote Control of Fetal Metabolism: Trophoblast mTOR Signaling Regulates Liver IGFBP-1 Phosphorylation and IGF-1 Bioavailability. Int J Mol Sci. 2023 Apr 14; 24(8).
-
Schaub JA, AlAkwaa FM, McCown PJ, Naik AS, Nair V, Eddy S, Menon R, Otto EA, Demeke D, Hartman J, Fermin D, O'Connor CL, Subramanian L, Bitzer M, Harned R, Ladd P, Pyle L, Pennathur S, Inoki K, Hodgin JB, Brosius FC, Nelson RG, Kretzler M, Bjornstad P. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. J Clin Invest. 2023 03 01; 133(5).
-
Roberson PA, Kincheloe GN, Welles JE, Xu D, Sam-Clarke M, MacLean PS, Lang CH, Jefferson LS, Kimball SR. Glucose-Induced Activation of mTORC1 is Associated with Hexokinase2 Binding to Sestrins in HEK293T Cells. J Nutr. 2023 04; 153(4):988-998.
-
Dahl KD, Almeida AR, Hathaway HA, Bourne J, Brown TL, Finseth LT, Wood TL, Macklin WB. mTORC2 Loss in Oligodendrocyte Progenitor Cells Results in Regional Hypomyelination in the Central Nervous System. J Neurosci. 2023 01 25; 43(4):540-558.
-
Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, Pine SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022 09 06; 21(9):1381-1392.
-
Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Th?lken M, Meyer LM, Nguyen TD, Campe J, Moser LM, Hock S, Baker F, Meyer CT, Wempe F, Serve H, Ullrich E, Jeremias I, M?nch C, Brandts CH. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2022 10; 36(10):2396-2407.
-
McGregor BA, Xie W, Adib E, Stadler WM, Zakharia Y, Alva A, Michaelson MD, Gupta S, Lam ET, Farah S, Nassar AH, Wei XX, Kilbridge KL, Harshman L, Signoretti S, Sholl L, Kwiatkowski DJ, McKay RR, Choueiri TK. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|